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Because of its potent immunomodulatory effect, an infusion of donor mononuclear early apoptotic cells
(ApoCell) was tested in addition to cyclosporine and methotrexate as prophylaxis for acute graft-versus-host
disease (GVHD) after HLA-matched myeloablative allogeneic hematopoietic stem cell transplantation (HSCT)
from a related donor. In a phase I/IIa clinical trial, we treated 13 patients (median age, 37 years; range, 20 to
59 years) with hematologic malignancies: 7 patients with acute lymphoblastic leukemia, 5 patients with
acute myeloid leukemia, and 1 patient with chronic myeloid leukemia, who received conventional myeloa-
blative conditioning, with 35, 70, 140, or 210  106 cell/kg of donor ApoCell, on day -1 of transplantation.
Engraftment was successful in all patients with median time to neutrophil recovery of 13 days (range, 11 to
19), and platelet recovery of 15 days (range, 11 to 59). Serious adverse effects were reported on 10 occasions in
the trial, all of which were considered unrelated (n ¼ 7) or unlikely to be related (n ¼ 3) to ApoCell infusion.
The nonrelapse mortality at day 100 and 180 after transplantation was 7.7% and the overall survival at 100 and
180 days after transplantation was 92% and 85%, respectively. All ApoCell preparations showed an in vitro
signiﬁcant tolerogenic effect upon interaction with dendritic cells. The overall incidence of acute grades II to
IV GVHD was 23%, whereas among those receiving the 2 higher doses (n ¼ 6), the rate was 0%. These results
suggest that a single infusion of donor ApoCell in HLA-matched allogeneic HSCT is a safe and potentially
effective prophylaxis for acute GVHD occurring after myeloablative conditioning. No dose limiting toxicity
was observed. (Clinicaltrials.gov no. NCT00524784).
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) remains a major
complication of allogeneic stem cell (HSCT) or bone marrow
transplantation [1,2] and the optimal approach for GVHD
prophylaxis has not yet been established. Current ap-
proaches for GVHD prophylaxis comprise the combination
of a calcineurin inhibitor (CNI), cyclosporine or tacrolimus,
and either methotrexate, mycophenolate mofetil, or siroli-
mus [3-7]. However, acute GVHD still occurs among 20% to
70% of bone marrow transplantation patients who receive
transplants from human leukocyte antigen (HLA)ematched
siblings, and even more frequently in unrelated donor
transplant recipients [2,8-11].
Although CNIs partially inhibit acute GVHD, they may
impair immune reconstitution by inhibiting T cell develop-
ment, thus increasing the risk of opportunistic infections and
disease relapse [12,13]. Therefore, patients with hematologic
malignancies undergoing allogeneic HSCT are in need of
GVHD prophylaxis, which would minimize the use of CNIs,
prevent GVHD, and yet retain a graft-versus-tumor effect.edgments on page 65.
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13.10.010ApoCell, a cell-based therapeutic modality composed of
matched-donor mononuclear-enriched early apoptotic cells,
is known to immunomodulate macrophages and dendritic
cells (DCs), both of which are critically involved in the
pathogenesis of GVHD [14]. After interaction with apoptotic
cells, macrophages have been shown to secrete the anti-
inﬂammatory cytokines, TGF-b and IL-10 [15], and down-
regulate NFkB expression and proinﬂammatory cytokines
[16]. Immature DCs are capable of phagocytosis of apoptotic
cells, and after their ingestion or even in their physical
presence alone, immature DCs may shut down a potentially
inﬂammatory response [17,18]. This effect can further trigger
the differentiation of regulatory T cells by DCs. Indeed, in
a murine model of GVHD, treating the animals with a single
dose of apoptotic cells inhibits the development of GVHD
and GVHD-related mortality in a T regulatoryedependent
manner [19,20].
Extracorpeal photopheresis, based on the biologic effects
of ultraviolet A lighteactivated 8-methoxypsoralen onmixed
leukocyte population collected by autologous apheresis and
reinfused into the patient, was suggested to have an immu-
nomodulatory action through several putative mechanisms,
including apoptosis induction. However, it includes a signif-
icant amount of late apoptotic cells [21],which are potentially
dangerous and could easily disintegrate. It is used in some
centers mainly to treat patients with corticosteroid-resistantTransplantation.
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not clearly established.
The ApoCell product is a cellular product containing allo-
geneic HLA-matched donor-enriched stable early apoptotic
mononuclear cells and is administered intravenously 24hours
before HSCT. We conducted a phase I/IIa, multicenter
(3 medical centers), open-label study designed to evaluate
the safety, tolerability, and preliminary efﬁcacy of ApoCell
administration (clinicaltrials.gov no. NCT00524784).METHODS
Study Design and Patients
The primary aim of this phase I/IIa study was to determine the safety
proﬁle and tolerability (dose limiting toxicity) of ApoCell infusion at
ascending doses in subjects undergoing allogeneic HLA-matched bone
marrow transplantation (alloBMT) from sibling donors up to 180 days after
transplantation.
The secondary aims were to determine the success rate for engraftment
and time to successful engraftment, describe the rates and grade of acute
GVHD after ApoCell infusion and the immunological function of the recip-
ient after ApoCell infusion and HSCT.
To evaluate these outcomes, the following endpoints were used: time to
neutrophil and platelet recovery; time to full donor chimerism in neutro-
phils; proportion of patients with primary or secondary graft failure; or
relapse of primary malignancy, deﬁned as disease-free survival from date of
HSCT to last follow up or relapse; incidence of infections (bacterial, viral, and
fungal); proportions of subjects surviving at day 45 (46 days after ApoCell
infusion), at day 100, and at day 180; the grade of acute GVHD after ApoCell
infusion; proportion of subjects who developed acute high-grade GVHD;
and time to onset of acute GVHD, as deﬁned by Przepiorka et al. [22].
The study was approved by the local ethics committees and Israeli
Ministry of Health and was performed according to institutional guidelines.
Written informed consent was obtained in accordance with the Declaration
of Helsinki from both patients and donors. Eligibility criteria included the
following: adult male or female subjects, 18 to 60 years of age, weighing at
least 40 kg at the time of screening visit, and with life expectancy of at least
6 months at the time of the baseline visit. Subjects were eligible if they were
about to undergo an HLA-matched alloBMT from a ﬁrst-degree relative
donor for any disease for which transplantation is appropriate, except
progressive or poorly controlled malignancies. The availability of an HLA-
identical sibling, and an HLA-matched ﬁrst-degree relative, with at least a
7/8 HLA match and a clinician decision to use myeloablative regimen, were
required. Donor eligibility included standard eligibility criteria for AlloBMT
with an additional signed informed consent for leukapheresis for the pur-
pose of apoptotic cell donation.
Exclusion criteria included pregnancy, positive serology for HIV, active
serious infection, T celledepleted allograft; Karnofsky performance status
less than 80%, or serious organ dysfunction (eg, left ventricular ejection
fraction < 40%, pulmonary forced vital capacity < 60% of predicted, liver
transaminases > 2.5  the upper limit of normal, serum bilirubin >3 mg/dL
or creatinine > 2.5 mg/dL). All transplants were prepared from mobilized
peripheral blood stem cells.
ApoCell was administered at the initial dose level (cohort 1) of 35  106
apoptotic cells/kg, on day -1 of transplantation in 1 patient to evaluate the
preliminary safety proﬁle of ApoCell before proceeding with recruitment of
an additional 2 subjects to the ﬁrst cohort. ApoCell infusion in the ﬁrst pa-
tient met the protocol-deﬁned safety criteria at day 45 and the study pro-
ceeded to the second recruited patient at the same dosage, which also met
the protocol-deﬁned criteria for safety. The study then proceeded to the
third patient and next phase. The next cohorts included 70, 140, and
210  106 cell/kg of donor ApoCell, for cohorts 2, 3, and 4, respectively. An
interim analysis of safety data was performed by the Data and Safety
Monitoring Board after cohorts 1 through 3 completed study day 31 and
cohort 4 completed study day 45. All cohorts met the Data and Safety
Monitoring Board criteria and the study was authorized to be completed.Conditioning Regimen and Supportive Care
Conditioning regimens for patients were either busulfan- or total body
irradiation (TBI)-based. For busulfan-based conditioning, the regimen was
as follows: per oral busulfan 16 mg/kg for 4 days with cytoxan 120 mg/kg or
Flu-Bu2-TT2 (ﬂudarabine 30 mg/kg/day for 5 or 6 days, i.v. busulfan, 3.2 mg/
kg/day for 2-4 days, and i.v. thiotepa 5 mg/kg/day for 2 days). For TBI-based
conditioning: fractionated TBI at a total dose of a 1200 cGy with cyclo-
phosphamide 60 mg/kg for 2 days i.v. or etoposide (VP-16) 60 mg/kg. Of
note, despite these indications, each participating center could employ
a conditioning regimen according to their local institution guidelinesprovided it was myeloablative and was used for all patients included in the
study at that center. A conditioning regimen including antithymocyte
globulin was prohibited (exclusion criteria).
Dosing was based on adjusted body weight and ApoCell infusions were
given intravenously on day -1 before transplantation.
GVHD Prophylaxis
All study subjects received GVHD prophylaxis regimen according to the
standard of care that included i.v. cyclosporine at a dose of 3 mg/kg initiated
on day 3 (with subsequent dose adjustment aiming trough plasma levels of
300 ng/mL) and i.v. methotrexate at doses of 15mg/m2, 10mg/m2, 10mg/m2
on days þ1, þ3 and þ6, respectively (3 doses of folinic acid were given
starting 18 hours after each dose). Cyclosporine was given orally when the
patient was able to swallow and continued until day þ90 (in accordance
with disease status and chimerism).
ApoCell-related Toxicity
Adverse events (AEs) were reported and graded in accordance with
Common Terminology Criteria for Adverse Events, version 3. Relationships
between the AE and ApoCell versus those typically associatedwith HSCTand
GVHD were carefully assigned in accordance with the guidance in the
clinical protocol. GVHD severity was determined clinically; however, bi-
opsies of affected organs were strongly encouraged, whenever possible.
The timing of the infusion of the ApoCell product at 24 to 30 hours
before alloBMT in all cohorts allowed an additional safety evaluation during
this period before the stem cell infusion.
Non-ApoCell Related Toxicity and Non-relapse Mortality (NRM)
Morbidity and mortality related to transplantation included reports of
serious AE (SAE) and documentation of graft failure, veno-occlusive disease
(VOD), sepsis or bacterial infections, noninfectious pneumonia, hemorrhage,
refractory GVHD, and multisystem organ failure. Nonfatal toxicity included
any SAE or documentation of grade IV ALT, AST, or bilirubin elevation
[23,24], grade III serum creatinine elevation [25], reversible VOD, hemor-
rhagic cystitis, pericardial effusion, or subdural hematoma.
Diagnosis and Treatment of GVHD
Acute GVHD was graded according to Przepiorka et al. [22] through day
100 of the study. However, acute GVHD was evaluated also between days
100 through 180. In the absence of histologic or clinical signs or symptoms of
chronic GVHD (see below), the persistence, recurrence, or new onset of
characteristic skin, gastrointestinal tract, or liver abnormalities should be
classiﬁed as acute GVHD regardless of the time after transplantation [26].
Chronic GVHD (cGHVD) was graded according to Filipovich et al. [26]
from day 100 through day 180. The broad category of chronic GVHD
included (1) classic chronic GVHD without features characteristic of acute
GVHD, and (2) an overlap syndrome in which features of chronic and acute
GVHD appear together.
Infection Assessments
All infection events were recorded and graded in accordance with the
National Cancer Institute Common Terminology Criteria for Adverse Events
version 3 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/ctcaev3.pdf). Time to infection was evaluated through day 180. CMV
was tested on screening, days 3, 10, 17, 31, 45, 66, 100, and 180 study visits.
Follow-up Visits
There were 3 follow-up periods: the acute follow-up period (days 1 to
3), short-term follow-up period (visits on days 10, 17, 31, and 45), and long-
term follow-up period (visits on days 66, 100, and 180). The window for
visits was  2 days for each weekly visit and  5 days for biweekly or more
visits during the follow-up periods.
Engraftment and Donor Chimerism
Neutrophil engraftment was deﬁned as an absolute neutrophil count
> 0.5  109/L for 3 consecutive measurements over 3 or more days. The ﬁrst
of the 3 days was designated the day of neutrophil engraftment. Platelet
engraftment was deﬁned as a platelet count > 20  109/L for 3 consecutive
measurements over 3 or more days without platelet support during the
preceding 3 days or in the 7 following days. The ﬁrst of the 3 days was
designated the day of platelet engraftment. The time to a platelet count
> 100  109/L was recorded as well.
Chimerism was assessed on days 10, 31, 45, 66, 100, and 180 using
quantitative PCR of informative polymorphic variable number tandem
repeat or short tandem repeat regions in the recipient and donor. Primary
graft failure was deﬁned as a lack of neutrophil recovery in the absence of
progressive malignancy affecting the marrow. Secondary graft failure was
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of progressive malignancy affecting the marrow.
Time to First Hospital Discharge
Time to ﬁrst hospital discharge was deﬁned as the time from the day of
HSCT (day 0) to the date of ﬁrst hospital discharge and was recorded as the
length of the initial hospital stay.
ApoCell Preparation
The ApoCell product consists of apoptotic cells produced from an
unmobilized mononuclear enriched cell fraction from a sibling HLA-
matched donor. Eligibility criteria for donors included the following: adult
males or females,18 to 65 years of age; bearing at least a 7/8 HLAmatchwith
the recipient; weight above 40 kg; and willingness to donate hematopoietic
blood mononuclear cells for the generation of ApoCell, in addition to the
donation for the HSCT. Eligible donors arrived at the clinic approximately at
day -19 for peripheral blood mononuclear harvesting using apheresis pro-
cedure (Cobe SpectraTM, Gambro BCT, Lakewood, CO) according to the local
hospital standard leukapheresis unit standard operating procedures. The
leukapheresis procedure was approximately 2.5 hours long, during which
7 liters of blood were processed and cells were collected at room temper-
ature into a transfer pack. Themean percentage of mononuclear cell fraction
in collections of the 13 donors was 88%  8% (range, 65% to 96%) and 1 to 3
collections were performed. The estimated yield of the enriched mono-
nuclear cell fraction from a donor was 1.0  1010 cells in an estimated vol-
ume of 100 mL to 140 mL, with some variability of cell yields according to
the donor. The collected mononuclear enriched cell fraction from the HLA-
matched donors underwent sequential processes for inducing early
apoptosis via a multistep procedure which included freezing and thawing of
the cells as a proapoptotic signal 1 and incubationwith methyl prednisolone
as a proapoptotic signal 2. In the ﬁrst stage, collected cells were washed,
resuspended in freezing medium (DMSO 10%) and underwent a gradual
freezing procedure. The freezing procedure constituted the signal 1 step in
the induction of early apoptosis. The cells were then stored in liquid nitrogen
until the transplantation date. Average time from cell collection to ApoCell
preparation was 18 days (range, 6 to 30 days).
About 24 hours before ApoCell infusion, the cryopreserved cells are
thawed (circulating water bath at 37C), washed, and then incubated in the
presence of 50 mg/mL methyl prednisolone for 6 hours to allow the signal 2
step for apoptosis induction. After the apoptotic cells are harvested, ApoCell
product undergoes a medium exchange with PBS to remove methyl pred-
nisolone before preparation of the ﬁnal product.
Population of late apoptotic cells appearing after thawing was elimi-
nated spontaneously by the speciﬁc incubation condition and by washing,
and the ﬁnal suspension of ApoCell contained at least 40% early apoptotic
cells (usually around 55% to 60%) deﬁned as Annexin-V-positive propidium
iodide (PI)-negative cells. Apoptosis was detected by double staining with
annexin V-FITC and propidium iodide (MBL, Japan) using ﬂow cytometry
(FACSCalibur, Becton Dickinson, San Jose, CA). The results were analyzed
using FCSexpress software. A total of 10,000 events were collected and 100%
of collected cells were analyzed. The positive staining for Annexin V was
determined by the deﬁnition of negative staining while eliminating Caþþ
from the sample buffer, which correlated very well to the unstained sample
that was generally used. Viable cells are negative for both Annexin V and PI;
early apoptotic cells expose phosphatidylserine (PS) but do not admit PI and,Table 1
Patient and Bone Marrow Transplantation Characteristics
Cohort and
Patient No.
Age Gender Weight Diagnosis Disease Severity;
HLA-Matching
Cohort 1-1 38 M 81 ALL CR1; 8/8
Cohort 1-2 38 F 64 ALL PR2; 8/8
Cohort 1-3 30 M 58 ALL CR1; 8/8
Cohort 2-1 25 M 77 ALL CR2; 8/8
Cohort 2-2 59 F 83 MDS, AML CR1; 8/8
Cohort 2-3 24 M 40 ALL CR1; 10/10
Cohort 2-4 58 M 78 MDS, AML CR1; 8/8
Cohort 3-1 49 M 100 MDS, AML CR1; 12/12
Cohort 3-2 37 M 96 MDS, AML CR1; 12/12
Cohort 3-3 23 M 85 ALL CR1; 12/12
Cohort 4-1 20 M 72 ALL CR1; 10/10
Cohort 4-2 37 F 51 CML Chronic phase; 10/10
Cohort 4-3 40 M 111 AML de novo CR1; 10/10
TBI indicates total body irradiation; ALL, acute lymphoblastic leukemia; AML, acut
plastic syndrome; CR1, ﬁrst complete remission; CR2, second complete remission;therefore, are Annexin V-positive but PI-negative. Late apoptotic cells
expose PS but also admit PI (due to damaged membrane) and, therefore, are
Annexin V-positive and PI-positive. The cell suspension for infusion was
prepared under current Good Manufacturing Procedures. Infusions were
administered 24 to 30 hours before HSCT and within 8 hours of completion
of preparation. Cells were stored at 2C to 8C until administration.
Potency Assay
A third-party immature DC (iDCs) were prepared 6 days before ApoCell
preparation as described in Verbovetski et al. [17]. ApoCell samples from
each batch were introduced to iDCs at 1:2,1:4, and 1:8 iDCs to ApoCell ratios
overnight. In some treatments, 2 hours after interaction, 10 ng/mL of lipo-
polysaccharide (LPS) was added. At the end of interaction, the cells were
harvested and stained with both DCsign and HLA-DR or CD86. Expression of
HLA-DR and CD86 on dendritic cells (DCsign positive cells) was evaluated
using ﬂow cytometry and the analysis was performed on gated DCsign
positive cells (10,000 events) using FCSexpress Software.
Statistical Analysis
Descriptive statistics were used to summarize outcome measures and
baseline characteristics. In this analysis, all available data were presented
with no imputation for any missing data. All subjects who received ApoCell
infusion were included in the safety analysis. Subjects contributed the data
available up to the point of withdrawal or study completion or death.
Descriptive statistics including means, median, standard deviation, mini-
mum and maximum values were used to summarize continuous variables.
Dichotomous variables were presented as count and percentages. Student
t-test (2-tail type 1) was used for potency assay analysis.
RESULTS
Patient, Donor, and Graft Characteristics
Follow-up data were available for 11 patients through day
180 and for 2 patients until the day of their death. Patient,
disease, and transplantation characteristics are summarized
in Table 1. The most common diagnosis was acute lympho-
blastic leukemia (ALL) (n ¼ 7, 54%), followed by acute
myeloid leukemia (AML) (n ¼ 5, 38%) and 1 patient with
chronic myeloid leukemia (CML) (n ¼ 1, 7.7%). Among pa-
tients with AML, 1 patient presented with disease de novo,
and 4 patients developed AML from an antecedent myelo-
dysplastic syndrome. A total of 5 patients with ALL were in
ﬁrst complete remission (CR1), 1 patient in second complete
remission (CR2), and 1 patient in second partial remission. A
total of 5 patients with AML were in CR1. The single patient
with CML was in chronic phase and was unresponsive to
3 tyrosine kinase inhibitor before transplantation. All pa-
tients received related donor allografts. The patients’ median
age was 37 years (range, 20 to 59). HLA-matching data are
presented at Table 1. The median total number of cell
transplanted and CD34þ cells infused into recipients wereConditioning Regimen
(Myeloablative)
Infused Cell Doses Total ( 108/kg)/
CD34þ( 106/kg)
Fludarabine busulphan thiotepa
cytarabine
12.5  108/kg/3.69  106/kg
Cyclophosphamide TBI 20.34  108/kg/22.38  106/kg
Cyclophosphamide, TBI 29.5  108/kg/7  106/kg
Cyclophosphamide TBI 10  108/kg/6.8  106/kg
Fludarabine busulphan thiotepa 13.6  108/kg/15.8  106/kg
Cyclophosphamide TBI 24.8  108/kg/8.1  106/kg
Fludarabine busulphan thiotepa 9.3  108/kg/18.6  106/kg
Busulphan cyclophosphamide 18  108/kg/7.2  106/kg
Busulphan cyclophosphamide 21.6  108/kg/9.7  106/kg
Cyclophosphamide TBI 19.3  108/kg/16.6  106/kg
Cyclophosphamide TBI 10.2  108/kg/6.35  106/kg
Busulphan cyclophosphamide 10.5  108/kg/7.19  106/kg
Fludarabine busulphan 11  108/kg/6.55  106/kg
e myeloblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodys-
PR2, second partial remission.
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(range, 3.7 to 22.4  106/kg), respectively (Table 1).
The initial plan was to recruit 3 patients for each cohort.
However the seventh patient received only 90  106 cells/kg
instead of 140 106 cells/kg and, therefore, was immediately
included in the second cohort (70  106 cells/kg) as an
additional patient. In total, 13 patients were treated: 3 in
cohorts 1, 3, and 4; and 4 patients in cohort 2. The patients
were treated consecutively between August 2009 and
January 2012; analysis was locked on July 2, 2012.Potency Assay
Potency was assessed using ﬂow cytometric evaluation of
DR and costimulatory molecules on DCs after exposure to
LPS, as explained in the methods section.
Tolerogenic DC can be generated upon interaction with
apoptotic cells [17] or apoptotic cell products [18]. For each
ApoCell preparation, we speciﬁcally examined the tolero-
genic effect of the prepared ApoCell using in vitro interaction
with iDCs. iDCs express a low level of HLA-DR and cos-
timulatory molecules. After exposure to maturation stimuli
such as LPS, iDCs undergo maturation and upregulate
expression levels of HLA- DR and costimulatory molecule
CD86. Potency assay results from 13 ApoCell preparations
infused to the patients are summarized in Table 2. The results
represent average percentage of inhibition in maturation of
LPS-treated DCs (inhibition in DR and CD86 expression) after
interactionwith ApoCell. As shown in Table 2, signiﬁcant and
dose-dependent downregulation was seen in all interaction
assays with ApoCell. Representative results from 1 patient’s
potency assay are shown in Figure 1.Engraftment
The median time to neutrophil recovery for all recipients
was 13 days (range, 11 to 19), and the median time to platelet
recovery was 15 days (range, 11 to 59). The median time to
neutrophil and platelets engraftment was 13 days (range, 13
to 14 days) and 17 days (range, 11 to 59) in the ﬁrst cohort
respectively; 14 (range, 11 to 17) and 14 (range, 11 to 18) in
the second cohort respectively; 14 days (range, 12 to 19) and
15 days (range, 13 to 54) in the third cohort respectively; and
12 days (range, 11 to 13) and 15 days (range, 13 to 17) in the
fourth cohort respectively.
All patients converted to donor type by day 66 (13 of 13).
Ten of 12 patients (83%) with available data on chimerism on
day 31 of the study were donor type and 2 were mixed
chimeras. One additional patient yielded no result due to
technical problems on day 31 and was found to be donor
type on the following visit (day 45). Primary graft failure didTable 2
Potency Assays
Marker DCs:ApoCell Ratio % Inhibition of Maturation by
LPS (n ¼ 13), mean  STD
P Value
DR 1:2 30.4  25.8 .0146
1:4 52.1  35.7 .0002
1:8 67.2  31.8 .0002
CD86 1:2 40.5  25.7 .0147
1:4 66.3  26.2 .0004
1:8 81.0  20.5 .0000
Average percentage of inhibition of DR and CD86 expression on DC mem-
brane after interaction with ApoCell. Student t-test was used for potency
assay analysis.
LPS indicates lipopolysaccharide; DC, dendritic cells.not occur. None of the patients with mixed chimerism at day
31 were found to have early disease relapse.
Adverse Events
Ten SAEs were reported during the study. All were found
to be not related (n ¼ 7) or unlikely to be related (n ¼ 3) to
ApoCell infusion. Documented SAEs include septic shock
(n ¼ 2, both considered not related to ApoCell infusion),
disease relapse (n¼ 2, both considered not related to ApoCell
infusion), hemorrhagic cystitis (n ¼ 1, considered not related
to ApoCell infusion), gastroenteritis due to adenovirus
infection (n ¼ 1, unlikely to be related to ApoCell infusion),
vomiting event (n ¼ 1, considered unlikely to be related to
ApoCell infusion), and febrile illness (n ¼ 3, 2 events
considered as not related and 1 unlikely to be related to
ApoCell infusion).
As expected in these patients, there were hundreds of AE,
but only 3 were reported as possibly related to ApoCell
infusion, and no AE were deﬁnitely or probably related to
ApoCell. AE included 1 episode of hypotension on the day of
the infusion (day 1), 1 transient throat irritation on the day
of the infusion (day 1), and 1 relapse on day 131 of the
study.
Infections
Reported infections are listed in Table 3.
Transplantation-related Toxicity (TRT)
One patient (7.7%) required dialysis due to renal failure
(grade III). The same patient experienced signiﬁcant hepa-
totoxicity deﬁned as bilirubin > 4 times upper normal levels
(7.7%, out of 13 patients), pericardial effusion (7.7%, out of 13
patients) and expired from relapse on day 103. Additionally,
2 patients (15.4%) experienced transient elevated creatinine
levels > 1.5 times the upper normal levels attributed to
dehydration and a medication, with no need for dialysis. One
patient was diagnosed with hemorrhagic cystitis. No patient
experienced VOD or subdural hematoma.
Relapse
The cumulative incidence of disease relapse at 100 days
and 180 days after transplantation was 7.7% (n ¼ 1) and 31%
(n ¼ 4), respectively. Diagnosis of relapse was on days 100,
131, 180, 187 (fever on day 168). Three of four patients with
relapse (75%) had ALL. All patients received cyclosporine.
Survival
Overall survival on day 45, 100, and 180, was 100%, 92.3%,
and 84.6%, respectively. Transplantation-related mortality
was 0% on day 45, 7.7% on day 100, and 7.7% on day 180.
Acute GVHD
Acute GVHDwas assessed through day 100 of the study in
12 out of 13 patients and through day 87 for the remaining
patient. Acute GVHD was assessed through day 180 of the
study in 10 out of 11 patients. All patients were included in
the day-100 cumulative incidence. The day-100 cumulative
incidences of grades II through IV and grade III or IV acute
GVHD for all patients were 23.1% and 15.4%, respectively
(Table 4). The median times to onset of grades II to IV and III
to IV acute GVHD were 31 days (range, 31 to 44 days) and
47 days (range, 31 to 62 days), respectively. None of the pa-
tients developed acute GVHD beyond day 100 after trans-
plantation. Ten of 11 patients were assessed for acute GVHD
at day 180. One of 10 patients was diagnosed with persistent
Figure 1. Potency assays. ApoCell potency was assessed using ﬂow cytometric evaluation of DR and the costimulatory molecule CD86 on dendritic cells (DCs) after
exposure to lipopolysaccharide (LPS), as explained in the methods section. Immature DCs express a low level of HLA-DR and costimulatory molecule CD86 (green
lines). After exposure to maturation stimuli, LPS, immature DCs undergo maturation and upregulate expression levels of HLA- DR and costimulatory molecule CD86
(red lines). Interaction with ApoCell at 1:2, 1:4, and 1:8, DCs: ApoCell ratios 2 hours before LPS exposure inhibits LPS induced HLA-DR and CD86 upregulation (blue
lines). A representative sample from 13 ApoCell preparations infused to the patients (summarized in Table 2).
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180 of the study. High-grade GVHD (grade II to IV) was
documented only in the 2 cohorts treated with the 2 lowest
doses of ApoCell (Figure 2A) and hepatic toxicity of acute
GVHD was documented only in the lowest dose treatment
with ApoCell (Figure 2B).
Chronic GVHD
Chronic GVHD was assessed from day 100 to day 180 of
the study in 10 out of 11 patients. Five of 10 patients (50%)
had mild chronic GVHD involving skin (n ¼ 4) and con-
junctiva (n ¼ 1).
Time to First Hospital Discharge
The mean time to ﬁrst hospital discharge for all patients
was 34.2 days (range, 15 to 103 days); 46.3 days (range, 15 to
103 days) in the ﬁrst cohort, 44.5 days (range, 20 to 87 days)
in the second cohort, 24.3 days (range, 22 to 28 days) in the
third cohort, and 18.3 days (range,17 to 21 days) in the fourth
(last cohort) (Figure 2C).
DISCUSSION
Acute GVHD is a signiﬁcant complication of alloBMT, with
death directly attributable to acute GVHD or its treatmentoccurring in approximately 10% to 20% of patients. Because
treatment of established acute GVHD can be nonefﬁcient and
is associated with a signiﬁcant morbidity and mortality, the
use of effective prophylaxis is of paramount importance.
ApoCell represents a novel mode of cellular therapy and
was tested for the ﬁrst time for safety and preliminary efﬁ-
cacy in GVHD prophylaxis and prevention in patients un-
dergoing allogeneic alloBMT.
The results presented here suggest that a single infusion
of donor ApoCell as prophylaxis for GVHD in myeloablative
HSCT is safe. ApoCell was given 24 hours before HSCT and no
related or possibly related SAEs speciﬁc to the ApoCell
infusionwere reported. A total of 10 SAE were reported, all of
which were assessed as not related (n ¼ 7) or unlikely to be
related (n ¼ 3) to ApoCell infusion. No deﬁnite or probable
adverse effects related to ApoCell were reported. In addition,
ApoCell infusions were not associated with prolongation of
time to engraftment, duration of hospitalization, chimerism
delay, increased mortality rate, or serious infections, when
compared with similar patients described in the literature
[2,27]. The incidences of acute grades II through IV and
grades III or IV GVHD were relatively low (23% and 15%,
respectively) in comparisonwith published data [2] showing
71% grade II to IV and 14% grade III to IV in last decade,
Table 3
Reported Infections
Patient
Cohort
Day Infection Type Cultured Organism Outcome Comments
Cohort 1-1 5 Acute dental and alveolar-abscess Noncharacterized Resolved
Cohort 1-2 1 UTI and septic shock Urine E. Coli Resolved Expired on day 103 from disease
relapse diagnosed on day 10020 Sepsis Blood Staphylococcus species Resolved
23 CMV infection PCR CMV Resolved
50 Bilateral pneumonia Noncharacterized Resolved
74 Oral infection Oral Klebsiella oxytoca, E. Coli Resolved
99 CMV reactivation Blood PCR CMV Ongoing
100 Ear infection Ear Streptococcus Pneumonia Ongoing
Cohort 1-3 11 Non-characterized pulmonary
inﬁltrates
Resolved
Cohort 2-1 5 Oral infection Oral Klebsiella, Proteus,
Enterobacter
Resolved
77 Flu Noncharacterized Resolved
Cohort 2-2 -1 UTI Klebsiella, Proteus, Enterobacter Resolved
2 Sepsis Aspergilus Resolved
5 Oral infection and UTI E. Coli Resolved
6 Sepsis Staphylococcus, Candida Troicali Resolved
21 UTI Urine Klebsiella, Proteus,
Enterobacter
Resolved
60 UTI Urine E. Coli Resolved
178 EBV reactivation Blood PCR Ongoing
Cohort 2-3 20 Pneumonia Staphylococcus Resolved
55 Sepsis Blood Staphylococcus epidermitis Resolved
59 Noncharacterized ear pain Unknown if an infection at all Resolved
Cohort 2-4 3 Gastrointestinal infection Clostridium difﬁcile Resolved Expired from septic shock on day
87 of the study17 Sepsis Blood Staphylococcus Resolved
28 UTI Urine Klebsiella, Proteus,
Enterobacter, E. Coli
Resolved
28 Upper respiratory infection Aspergillus, E. Coli Resolved
47 Pneumomia and sepsis Blood Staphylococcus Ongoing
75 Upper respiratory infection Pseudomonas Ongoing
79 Sepsis Blood Aspergillus Ongoing
84 Pheumonia Aspergillus Ongoing
Cohort 3-1 2 Catheter (intravenous) Klebsiella, Proteus, Enterobacter Resolved
20 Gastrointestinal infection Clostridium Resolved
45 Sepsis Blood Polyomavirus BK virus Resolved
131 Sepsis Blood Streptococcus Resolved
131 Rectal abscess Klebsiella, Proteus, Enterobacter Resolved
Cohort 3-2 3 Upper respiratory infection
catheter (intravenous), sepsis
Staphylococcus, blood E.Coli Resolved Disease relapse on day 131
14 Upper respiratory infection Mixed ﬂora Resolved
45 Upper respiratory infection Noncharacterized Resolved
75 Gastrointestinal infection Adenovirus Resolved
103 Gastrointestinal infection Clostridium difﬁcile Resolved
114 UTI Staphylococcus nadmolyticus Resolved
117 Oral infection and sepsis Oral Candida and blood Aspergillus Resolved
173 Rectal infection Klebsiella
Septic shock Noncharacterized Ongoing
Cohort 3-3 3 Pneumonia Non-characterized Resolved
4 Sepsis Blood Klebsiella, Proteus,
Enterobacter
Resolved
8 Catheter infection Noncharacterized Resolved
23 UTI Polyomavirus BK virus Resolved
27 Sepsis Blood Staphylococcus Resolved
125 Sepsis Blood Cornebacterium Resolved
Cohort 4-1 -2 Skin infection Pseudomonas Resolved
63 Fever Noncharacterized Resolved
Cohort 4-2 1 UTI Gram-positive coccus and other
mycobacteria
Resolved
6 Gum infection Noncharacterized Recovered with sequelae
7 Catheter (intravenous) infection Noncharacterized Resolved
Cohort 4-3 10 Fever Noncharacterized Resolved
64 Lung infection Noncharacterized viral infection Resolved
140 Catheter (intravenous) infection
and sepsis
Mixed ﬂora Resolved
The infections occurred during 180 days of follow-up.
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viously with some interventions. Remarkably, in the 2 higher
dosages there was no observed acute GVHD grade II to IV and
although these 2 cohorts included only 6 patients, it suggestsboth promising potential for very effective prophylactic
treatment. In addition, although, grade II to IV GVHDwas not
observed at the 2 higher doses, grade I acute GVHD was
increased to 50% in the same cohorts and mild chronic GVHD
Table 4
Maximal Overall Acute GVHD Grading Through Day 180 of the Study
Patient Cohort Maximal Overall aGVHD Grading
Through Day 180 of the Study
aGVHD Clinical
Features
Grade II to IV Grade III to IV Grade I Skin Liver Gut
Cohort 1-1   þ þ  
Cohort 1-2 þ þ   þ 
Cohort 1-3   þ þ  
Cohort 2-1      
Cohort 2-2      
Cohort 2-3 þ   þ  þ
Cohort 2-4 þ þ    þ
Cohort 3-1   þ þ  
Cohort 3-2   þ þ  
Cohort 3-3      
Cohort 4-1      
Cohort 4-2      
Cohort 4-3   þ þ  
Figure 2. Clinical course of aGVHD. Cohort 1 (3 patients), 2 (4 patients), 3 (3
patients), and 4 (3 patients) are presented. Figure 2A shows total incidence of
aGVHD grade II to IV by cohorts. Figure 2B shows total incidence of hepato-
toxicity by cohorts. Figure 2C shows time to the ﬁrst hospital discharge by
cohorts. Time to ﬁrst hospital discharge is deﬁned as the time from the day of
HSCT (day 0) to the day of ﬁrst hospital discharge.
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might possibly suggest that ApoCell treatment, as a physio-
logical modality, is reducing high-grade GVHD rather than
abolishing it. The response should be further evaluated in a
controlled study using 1 or 2 of the higher doses that showed
better GVHD results and also a tendency towards a shorter
time to ﬁrst hospital discharge and rate of infections.
The question regarding the possible loss of graft-versus-
tumor effect arises in every successful treatment that
potentially avoids high-grade acute GVHD, as this effect was
found to correlate with the severity of GVHD [28]. In the
present study, there were 4 patients with a relapse docu-
mented in 180 days and this aspect should be given attention
in further randomized studies. However, 75% of relapses
occurred in patients with ALL (3 of 4 patients) who tend to
have a higher rate of relapse in similar age groups [29,30]. In
addition, 1 of these 3 patients with ALL was in CR2 and 1 in
second partial remission.
The next question that needs to be addressed is: What is
the mechanism by which ApoCell reduces high-grade
GVHD? The present understanding of the GVHD mecha-
nism suggests a mechanism inwhich a “dangerous” cytokine
and inﬂammatory storm occurs during the conditioning and
early period of transplantation, where recipient dendritic
cells and donor T cells play a critical role together with
additional cells such as NK cells and IL-12 secreting dendritic
cells [31,32]. Plamacytoid dendritic cells and TH17 immune
response may further shape the response in gastrointestinal
GVHD [33]. Apoptotic cells have been shown to immuno-
modulate dendritic cells and macrophages and to render
them tolerogenic and inhibit proinﬂammatory activities such
as secretion of proinﬂammatory cytokines and expression of
costimulatory molecules [17]. Indeed, every ApoCell prepa-
ration was tested upon preparation for an in vitro immuno-
modulatory effect and had successfully inhibited DC LPS
triggering (Table 2, Figure 1). In murine models, it has been
further shown that, after interaction between antigen pre-
senting cells and apoptotic cells, T regulatory cells are
generated that further downregulate the GVHD storm.
Additional mechanisms, including STAT signaling inhibition
[34] and NFkB inhibition [16], may also have a critical role.
Taken together, their effect seems to intervene in the pro-
gression and development of GVHD. In support of that are
the in vitro potency assay that clearly showed inhibition of
iDC maturation after interaction with ApoCell. ApoCell
treatment suggests a novel modality of GVHD preventionthat uses a physiological way of downregulating the immune
response, inducing immune tolerance rather than immune
suppression and that differs from drugs that are effective but
carry a high risk of immune suppression with its inherent
dangers.
In summary, we have shown that a single infusion of
donor early mononuclear stable apoptotic cells as prophy-
laxis for acute GVHD in myeloablative HSCT is safe and
potentially effective and should be further evaluated in larger
randomized controlled studies.
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